OBJECTIVE: To review the efficacy and safety of atorvastatin in the treatment of
dyslipidemias. DATA SOURCES: A MEDLINE search (January 1960–April 1998), Current …

Synopsis Atorvastatin is a synthetic HMG-CoA reductase inhibitor which lowers plasma
cholesterol levels by inhibiting endogenous cholesterol synthesis. It also reduces …

Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of …

Atorvastatin is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor. In dosages of 10 to 80 mg/day, atorvastatin reduces levels of total cholesterol, low …

Background: Coronary heart disease (CHD) is the number one cause of death in Western
societies. Elevated levels of plasma low-density lipoprotein (LDL) cholesterol and triglycer …

Background Statins (3-hydroxy-3-methylglutaryl–coenzyme A [HMG-CoA] reductase
inhibitors) have been used for a decade to lower low-density lipoprotein (LDL) cholesterol …

The focus of lipid-lowering therapy with drugs is prevention of complications of
atherosclerosis. Landmark clinical trials have demonstrated that lowering low density …

Hypercholesterolemia is a major risk factor for the development of coronary heart disease.
HMG-CoA reductase inhibitors have been used as first-line drugs because of both their …

This randomized, placebo-controlled, double-masked, parallel-group trial assessed the
serum cholesterol—lowering effects of atorvastatin, a new 3-hydroxy-3-methylglutaryl …

Abstract This 24-week, randomized, open-label multicenter study evaluated the efficacy and
safety of atorvastatin compared with fenofibrate in the treatment of patients with combined …